Table 3. Key completed studies of immunotherapy in early stage NSCLC.

Reference (trial)	Phase	Stage	A/NA	Other key selection criteria	Agent	No. of participants	Primary endpoint	Key results
Yi 2017 (TOP1201)**	II	IB–IIIA	NA	–	Ipilimumab ×2 cycles, with platinum doublet chemotherapy ×3 cycles	24	% of subjects with detectable circulating T cells after treatment	Increased activation of CD4/CD8 T cells with ipilimumab, though primary endpoint not met
Yang 2018 (TOP1201)**	II	II–IIA	NA	–	Ipilimumab ×2 cycles, with platinum doublet chemotherapy ×3 cycles	13	Surgical outcomes	90-day mortality (1% and 0%) in preoperative chemotherapy alone versus ipilimumab groups, respectively. No increase in adverse surgical outcomes (P values not reported)
Forde 2018 (NA_00092076)**	II	I–IIA	NA	–	Nivolumab ×2 cycles	21	Safety	Few side effects, no treatment-related delays in surgery, and major pathological response in 45% of resected tumors

**, indicates single-arm study. NSCLC, non-small cell lung cancer.